Evidence map›Paper›PMID 30011896›Full record

ArticleBrain sciences2018

Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.

Stefania Bonaccorso, Antonio Metastasio, Angelo Ricciardi, Neil Stewart, Leila Jamal, Naasir-Ud-Dinn Rujully, Christos Theleritis, Stefano Ferracuti, Giuseppe Ducci, Fabrizio Schifano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Stefania BonaccorsoHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. stefania.bonaccorso@kcl.ac.uk.
Antonio MetastasioHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. antonio.metastasio@candi.nhs.uk.
Angelo RicciardiHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. angelo.ricciardi@candi.nhs.uk.
Neil StewartHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. Neil1.Stewart@candi.nhs.uk.
Leila JamalHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. leila.jamal@candi.nhs.uk.
Naasir-Ud-Dinn RujullyHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London NW1 0PE, UK. naasir-ud-dinn.rujully@candi.nhs.uk.
Christos TheleritisDepartment of Psychosis Studies, King's College London, London WC2R 2LS, UK. christos.theleritis@kcl.ac.uk.
Stefano FerracutiDepartment of Human Neurosciences, University of Rome 'La Sapienza', 00185 Rome, Italy. stefano.ferracuti@uniroma1.it.
Giuseppe DucciDepartment of Mental Health, ASL Rome 1, 00135 Rome, Italy. giuseppe.ducci@aslroma1.it.ORCID 0000-0002-1522-0642
Fabrizio SchifanoDepartment of Psychopharmacology, University of Hertfordshire, Hertfordshire AL10 9AB, UK. f.schifano@herts.ac.uk.
Camden and Islington NHS Foundation Trust · GBAzienda Sanitaria Locale Roma 3 · ITKing's College London · GBSapienza University of Rome · ITUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical presentations, analytical toxicology and clinical management plans of patients presenting with psychosis and SCRAs misuse.

methodsWe gathered information regarding the clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were collected using urine drug screening tests for traditional psychoactive substances and NPS.

resultsWe described the clinical presentation and management plan of four patients with psychosis and misuse of SCRAs.

conclusionThe formulation of an informed clinical management plan requires a structured assessment, identification of the index NPS, pharmacological interventions, increases in nursing observations, changes to leave status and monitoring of the vital signs. The objective from using these interventions is to maintain stable physical health whilst rapidly improving the altered mental state.

Indexed as

antipsychoticsmental healthnovel psychoactive substancesNPSNPS testingnursing carephysical healthpsychosisSCRAssynthetic cannabinoids

Identifiers

PMID30011896
PMCPMC6071094
OpenAlexW2883394336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.